摘要
目的探讨精神分裂症患者予以舒肝解郁胶囊辅助治疗对其抑郁症状的作用。方法选取2016年1月28日至2017年1月24日温岭市精神康复医院82例精神分裂症患者为研究对象,所有患者存在抑郁症状,采用随机数字表法分为两组,每组41例。两组均采取常规治疗,在此基础上,对照组使用喹硫平治疗,观察组使用舒肝解郁胶囊治疗。观察两组病情改善及不良事件发生情况。结果观察组治疗2周、1个月后汉密尔顿抑郁量表(HAMD)评分低于对照组,分别为(16.97±2.23)分、(12.53±1.88)分(t=3.06、5.52,P<0.05);观察组治疗1周、2周、1个月后简明精神病量表(BPRS)评分均低于对照组,分别为(30.29±2.41)分、(25.47±2.59)分、(21.03±2.77)分(t=6.17、6.60、10.20,P<0.05);阳性和阴性症状量表(PANSS)评分方面,观察组治疗1周、2周、1个月分别为(72.76±3.83)分、(41.50±3.46)分、(33.94±2.89)分,优于对照组(t=4.02、12.25、13.40,P<0.05);观察组不良事件发生率[4.88%(2/41)]显著低于对照组[19.51%(8/41)](χ^2=4.10,P<0.05);观察组3个月、6个月后复发率分别为7.32%(3/41)、12.20%(5/41),低于对照组的26.83%(11/41)、34.15%(14/41)(χ^2=5.51、5.55,均P<0.05)。结论舒肝解郁胶囊应用于精神分裂症辅助治疗中,可有效改善患者抑郁症状。
Objective To investigate the effect of Shugan Jiayu capsule on depression in patients with schizophrenia. Methods From January 28, 2016 to January 24, 2017, 82 schizophrenic patients in Wenling Psychiatric Rehabilitation Hospital were selected in the study.All the patients had depressive symptoms and were divided into two groups by random number table method, with 41 cases in each group.Both two groups were treated with routine therapy.The control group was treated with quetiapine, and the observation group was given Shugan Jieyu capsule.The improvement of the disease and the occurrence of adverse events in the two groups were observed. Results At two weeks and one month after treatment, the Hamilton Depression Scale(HAMD) scores of the observation group[(16.97±2.23)points and (12.53±1.88)points] were lower than those of the control group (t=3.06, 5.52, all P<0.05). After one week, two weeks and one month of treatment, the Brief Psychiatric Rating Scale(BPRS) scores of the observation group[(30.29±2.41)points,(25.47±2.59) and (21.03±2.77)points] were lower than those of the control group (t=6.17, 6.60, 10.20, all P<0.05). After one week, two weeks and one month of treatment, the Positive and Negative Symptom Scale(PANSS) scores of the observation group were (72.76±3.83)points,(41.50±3.46)points and (33.94±2.89)points, respectively, which were better than those of the control group(t=4.02, 12.25, 13.40, all P<0.05). The incidence rate of adverse events in the observation group[4.88%(2/41)] was obviously lower than that in the control group[19.51%(8/41)](χ^2=4.10, P<0.05). The recurrence rates of the observation group after 3 months and 6 months were 7.32%(3/41) and 12.20%(5/41), respectively, which were lower than those of the control group[26.83%(11/41) and 34.15%(14/41)](χ^2=5.51, 5.55, P<0.05). Conclusion Shugan Jieyu capsule can effectively improve the depressive symptoms of schizophrenia patients.
作者
陈志兴
Chen Zhixing(Department of Psychiatry, Wenling Psychiatric Rehabilitation Hospital, Wenling, Zhejiang 317515, China)
出处
《中国基层医药》
CAS
2019年第10期1190-1193,共4页
Chinese Journal of Primary Medicine and Pharmacy
基金
浙江省温岭市科技计划项目(2013C31104).
